Segall Bryant & Hamill LLC lifted its holdings in shares of Innophos Holdings, Inc. (NASDAQ:IPHS) by 10.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,090,307 shares of the specialty chemicals company’s stock after buying an additional 105,965 shares during the period. Innophos makes up about 1.0% of Segall Bryant & Hamill LLC’s investment portfolio, making the stock its 26th largest holding. Segall Bryant & Hamill LLC owned about 5.58% of Innophos worth $43,841,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Ramsey Quantitative Systems acquired a new stake in Innophos in the fourth quarter worth approximately $134,000. Vident Investment Advisory LLC acquired a new stake in Innophos in the fourth quarter worth approximately $201,000. Alps Advisors Inc. acquired a new stake in Innophos in the fourth quarter worth approximately $213,000. GW&K Investment Management LLC acquired a new stake in Innophos in the first quarter worth approximately $222,000. Finally, Verition Fund Management LLC acquired a new stake in Innophos in the first quarter worth approximately $237,000. Institutional investors and hedge funds own 95.27% of the company’s stock.
Shares of NASDAQ:IPHS traded up $0.13 on Thursday, reaching $48.59. 459 shares of the company traded hands, compared to its average volume of 126,213. Innophos Holdings, Inc. has a fifty-two week low of $38.66 and a fifty-two week high of $51.34. The company has a market capitalization of $959.44 million, a PE ratio of 19.75 and a beta of 0.83. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.70 and a current ratio of 3.22.
Innophos (NASDAQ:IPHS) last announced its quarterly earnings data on Tuesday, May 1st. The specialty chemicals company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.06. Innophos had a return on equity of 14.26% and a net margin of 2.95%. The company had revenue of $205.00 million during the quarter, compared to the consensus estimate of $196.91 million. During the same quarter in the prior year, the firm earned $0.59 EPS. The company’s quarterly revenue was up 23.5% compared to the same quarter last year. research analysts forecast that Innophos Holdings, Inc. will post 2.7 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 5th. Shareholders of record on Friday, May 18th were paid a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 3.95%. The ex-dividend date of this dividend was Thursday, May 17th. Innophos’s dividend payout ratio (DPR) is currently 78.05%.
IPHS has been the subject of a number of recent research reports. BidaskClub upgraded Innophos from a “hold” rating to a “buy” rating in a research report on Wednesday, June 6th. Zacks Investment Research upgraded Innophos from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research report on Wednesday, May 9th. Finally, TheStreet upgraded Innophos from a “c+” rating to a “b” rating in a research report on Wednesday, May 30th.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.